Premium
The Use of Drug‐Eluting Stents in the Management of Transplant Renal Artery Stenosis
Author(s) -
Abate M. T.,
Kaur J.,
Suh H.,
Darras F.,
Mani A.,
Nord E. P.
Publication year - 2011
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2011.03652.x
Subject(s) - medicine , renal function , creatinine , surgery , stenosis , blood pressure , stent , transplantation , kidney transplantation , renal artery stenosis , retrospective cohort study , incidence (geometry) , renal artery , cardiology , kidney , physics , optics
Transplant renal artery stenosis (TRAS) is a common occurrence following kidney transplantation with an incidence rate ranging from 6% to 23%. A single‐center retrospective study was conducted to examine the use of drug‐eluting stents (DES) in eligible patients with hemodynamically significant TRAS. Between March 2008 and January 2011, 12 patients were diagnosed with TRAS with reference vessel diameter measuring <5 mm and underwent endovascular intervention (EVI) with DES placement. TRAS was detected within the first year posttransplantation in a majority of these patients (83%) and manifested as hypertension (100%), allograft dysfunction (100%) and edema (58%). Procedural success rate was 100%. Patients were followed for a mean period of 16 ± 10 months. Blood pressure improved from a mean of 156/82 to 138/73 mmHg at the end of the follow‐up period. In 11/12 patients, serum creatinine improved from 3.1 ± 1.3 mg/dL to 2.3 ± 0.5 mg/dL at the end of the follow‐up period. TRAS of early onset is readily amenable to EVI with stent placement resulting in improvement in blood pressure control and allograft function.